Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma.

Knight WRC, Zylstra J, Wulaningsih W, Van Hemelrijck M, Landau D, Maisey N, Gaya A, Baker CR, Gossage JA, Largergren J, Davies AR; Guy's and St Thomas' Oesophago‐Gastric Research Group.

BJS Open. 2018 Apr 23;2(4):229-237. doi: 10.1002/bjs5.65. eCollection 2018 Aug.

2.

Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.

Davies AR, Myoteri D, Zylstra J, Baker CR, Wulaningsih W, Van Hemelrijck M, Maisey N, Allum WH, Smyth E, Gossage JA, Lagergren J, Cunningham D, Green M; Guy's and St Thomas' Oesophago-Gastric Research Group and PROGRESS Study Group.

Br J Surg. 2018 Jul 26. doi: 10.1002/bjs.10900. [Epub ahead of print]

PMID:
30047556
3.

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.

Wulaningsih W, Garmo H, Ahlgren J, Holmberg L, Folkvaljon Y, Wigertz A, Van Hemelrijck M, Lambe M.

Breast Cancer Res Treat. 2018 Jul 21. doi: 10.1007/s10549-018-4890-z. [Epub ahead of print]

PMID:
30030708
4.

Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy.

Knight WRC, Zylstra J, Van Hemelrijck M, Griffin N, Jacques AET, Maisey N, Baker CR, Gossage JA, Largergren J, Davies AR.

BJS Open. 2018 Mar 15;1(6):182-190. doi: 10.1002/bjs5.30. eCollection 2017 Dec.

5.

Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria.

Van Hemelrijck M, Ulmer H, Nagel G, Peter RS, Fritz J, Myte R, van Guelpen B, Föger B, Concin H, Häggström C, Stattin P, Stocks T.

PLoS One. 2018 Jun 13;13(6):e0197830. doi: 10.1371/journal.pone.0197830. eCollection 2018.

6.

Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus.

Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, Coolen ACC, Holmberg L.

Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31587. [Epub ahead of print]

PMID:
29744858
7.

Cognitive training for technical and non-technical skills in robotic surgery: a randomised controlled trial.

Raison N, Ahmed K, Abe T, Brunckhorst O, Novara G, Buffi N, McIlhenny C, van der Poel H, van Hemelrijck M, Gavazzi A, Dasgupta P.

BJU Int. 2018 May 7. doi: 10.1111/bju.14376. [Epub ahead of print]

PMID:
29733492
8.

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.

Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M.

PLoS One. 2018 Apr 12;13(4):e0195690. doi: 10.1371/journal.pone.0195690. eCollection 2018.

9.

Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M.

Eur Urol. 2018 Sep;74(3):261-280. doi: 10.1016/j.eururo.2018.02.026. Epub 2018 Mar 26. Review.

PMID:
29598981
10.

Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.

Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, Van Hemelrijck M.

Transl Androl Urol. 2018 Feb;7(1):83-97. doi: 10.21037/tau.2017.12.24. Review.

11.

The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.

Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S.

Urol Oncol. 2018 Jun;36(6):309.e15-309.e23. doi: 10.1016/j.urolonc.2018.02.016. Epub 2018 Mar 22.

PMID:
29576269
12.

Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.

Nowinski S, Santaolalla A, O'Leary B, Loda M, Mirchandani A, Emberton M, Van Hemelrijck M, Grigoriadis A.

Oncotarget. 2018 Feb 5;9(16):12812-12824. doi: 10.18632/oncotarget.24400. eCollection 2018 Feb 27.

13.

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, Holmberg L, Adolfsson J, Van Hemelrijck M.

BMJ Open. 2018 Mar 16;8(3):e020787. doi: 10.1136/bmjopen-2017-020787.

14.

Determinants of cancer screening awareness and participation among Indonesian women.

Anwar SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, Watkins J, Wulaningsih W; PILAR Research Network.

BMC Cancer. 2018 Mar 6;18(1):208. doi: 10.1186/s12885-018-4125-z.

15.

Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.

Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, Van Hemelrijck M.

BMC Cancer. 2018 Feb 20;18(1):205. doi: 10.1186/s12885-018-4111-5.

16.

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.

Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, Adolfsson J, Stattin P, Carroll P, Van Hemelrijck M.

Ecancermedicalscience. 2018 Jan 25;12:802. doi: 10.3332/ecancer.2018.802. eCollection 2018. Review.

17.

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.

Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M.

Oncotarget. 2017 Dec 4;9(1):774-782. doi: 10.18632/oncotarget.22891. eCollection 2018 Jan 2.

18.

Recent advances in understanding and managing aortic stenosis.

Van Hemelrijck M, Taramasso M, De Carlo C, Kuwata S, Regar E, Nietlispach F, Ferrero A, Weber A, Maisano F.

F1000Res. 2018 Jan 16;7:58. doi: 10.12688/f1000research.11906.1. eCollection 2018. Review.

19.

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.

Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, Gillett CE, Madden SF, Burchell JM, Kordasti S, Diebold SS, Spicer JF, Arnold JN.

Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. doi: 10.1158/1078-0432.CCR-17-2587. Epub 2018 Jan 16.

PMID:
29339440
20.

Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

Int J Cancer. 2018 Jun 1;142(11):2254-2262. doi: 10.1002/ijc.31256. Epub 2018 Jan 26.

PMID:
29322512
21.

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date.

Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

BJU Int. 2018 May;121(5):737-744. doi: 10.1111/bju.14106. Epub 2018 Jan 18.

PMID:
29247473
22.

Human development and its impact on genitourinary cancers.

Van Hemelrijck M.

BJU Int. 2017 Dec;120(6):747-748. doi: 10.1111/bju.13914. No abstract available.

PMID:
29168334
23.

King's Health Partners' Prostate Cancer Biobank (KHP PCaBB).

Saifuddin SR, Devlies W, Santaolalla A, Cahill F, George G, Enting D, Rudman S, Cathcart P, Challacombe B, Dasgupta P, Galustian C, Chandra A, Chowdhury S, Gillett C, Van Hemelrijck M.

BMC Cancer. 2017 Nov 22;17(1):784. doi: 10.1186/s12885-017-3773-8.

24.

A comparison of the left thoracoabdominal and Ivor-Lewis esophagectomy.

Davies AR, Zylstra J, Baker CR, Gossage JA, Dellaportas D, Lagergren J, Findlay JM, Puccetti F, El Lakis M, Drummond RJ, Dutta S, Mera A, Van Hemelrijck M, Forshaw MJ, Maynard ND, Allum WH, Low D, Mason RC.

Dis Esophagus. 2018 Mar 1;31(3). doi: 10.1093/dote/dox129.

PMID:
29087474
25.

The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.

Sheill G, Brady L, Guinan E, Hayes B, Casey O, Greene J, Vlajnic T, Cahill F, Van Hemelrijck M, Peat N, Rudman S, Hussey J, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, Mucci L, Sheils O, O'Leary J, O'Donnell DM, McDermott R, Finn S.

Trials. 2017 Oct 4;18(1):456. doi: 10.1186/s13063-017-2201-3.

26.

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):260-267. doi: 10.1111/bju.14023. Epub 2017 Oct 17.

PMID:
28940667
27.

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.

Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.

28.

Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.

Lee SM, Liyanage SH, Wulaningsih W, Wolfe K, Carr T, Younis C, Van Hemelrijck M, Popert R, Acher P.

Urol Oncol. 2017 Nov;35(11):664.e11-664.e18. doi: 10.1016/j.urolonc.2017.07.018. Epub 2017 Aug 8.

PMID:
28801025
29.

Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?

Van Hemelrijck M, Karagiannis SN, Rohrmann S.

Cancer Immunol Immunother. 2017 Dec;66(12):1557-1562. doi: 10.1007/s00262-017-2048-1. Epub 2017 Aug 9.

PMID:
28795218
30.

Pathological Concordance between Prostate Biopsies and Radical Prostatectomy Using Transperineal Sector Mapping Biopsies: Validation and Comparison with Transrectal Biopsies.

Marra G, Eldred-Evans D, Challacombe B, Van Hemelrijck M, Polson A, Pomplun S, Foster CS, Brown C, Cahill D, Gontero P, Popert R, Muir G.

Urol Int. 2017;99(2):168-176. doi: 10.1159/000471491. Epub 2017 Jul 29.

PMID:
28768264
31.

Real World Evidence: A Quantitative and Qualitative Glance at Participant Feedback from a Free-Response Survey Investigating Experiences of a Structured Exercise Intervention for Men with Prostate Cancer.

Fox L, Cahill F, Burgess C, Peat N, Rudman S, Kinsella J, Cahill D, George G, Santaolalla A, Van Hemelrijck M.

Biomed Res Int. 2017;2017:3507124. doi: 10.1155/2017/3507124. Epub 2017 Jul 3.

32.

Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, Cook G, Cahill D, Santa Olalla A, Cahill F, George G, Rudman S, Van Hemelrijck M.

BMC Cancer. 2017 Jul 21;17(1):494. doi: 10.1186/s12885-017-3458-3.

33.

Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.

Eur Urol. 2017 Dec;72(6):920-928. doi: 10.1016/j.eururo.2017.06.036. Epub 2017 Jul 12.

34.

Use of a handheld terahertz pulsed imaging device to differentiate benign and malignant breast tissue.

Grootendorst MR, Fitzgerald AJ, Brouwer de Koning SG, Santaolalla A, Portieri A, Van Hemelrijck M, Young MR, Owen J, Cariati M, Pepper M, Wallace VP, Pinder SE, Purushotham A.

Biomed Opt Express. 2017 May 9;8(6):2932-2945. doi: 10.1364/BOE.8.002932. eCollection 2017 Jun 1.

35.

The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort.

Nderitu P, Bosco C, Garmo H, Holmberg L, Malmström H, Hammar N, Walldius G, Jungner I, Ross P, Van Hemelrijck M.

Int J Cancer. 2017 Sep 15;141(6):1148-1160. doi: 10.1002/ijc.30818. Epub 2017 Jun 21.

PMID:
28577304
36.

Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.

MacAskill F, Lee SM, Eldred-Evans D, Wulaningsih W, Popert R, Wolfe K, Van Hemelrijck M, Rottenberg G, Liyanage SH, Acher P.

Int Urol Nephrol. 2017 Aug;49(8):1335-1342. doi: 10.1007/s11255-017-1609-8. Epub 2017 May 5.

PMID:
28477301
37.

Who is at risk of death from nephrectomy? An analysis of thirty-day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit.

Fernando A, Fowler S, Van Hemelrijck M, O'Brien T; British Association of Urological Surgeons (BAUS).

BJU Int. 2017 Sep;120(3):358-364. doi: 10.1111/bju.13842. Epub 2017 Apr 24.

PMID:
28440053
38.

Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study.

Yiu A, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Oncotarget. 2017 Jun 27;8(26):42332-42342. doi: 10.18632/oncotarget.16198.

39.

Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):209-216. doi: 10.1111/bju.13880. Epub 2017 May 17.

PMID:
28418195
40.

Your next clinical cancer research project: preparation in a multidisciplinary environment is key.

Van Hemelrijck M, Bosco C.

Ecancermedicalscience. 2017 Mar 14;11:ed64. doi: 10.3332/ecancer.2017.ed64. eCollection 2017.

41.

Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M.

BMC Cancer. 2017 Apr 4;17(1):246. doi: 10.1186/s12885-017-3232-6.

42.

Serum inflammatory markers and colorectal cancer risk and survival.

Ghuman S, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Br J Cancer. 2017 May 9;116(10):1358-1365. doi: 10.1038/bjc.2017.96. Epub 2017 Apr 4.

43.

Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.

Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, Gunnlaugsson A, Widmark A, Van Hemelrijck M.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1026-1031. doi: 10.1016/j.ijrobp.2017.01.218. Epub 2017 Feb 1.

44.

Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.

Shackshaft L, Van Hemelrijck M, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Breast Cancer Res. 2017 Mar 6;19(1):22. doi: 10.1186/s13058-017-0816-7.

45.

A latent class model for competing risks.

Rowley M, Garmo H, Van Hemelrijck M, Wulaningsih W, Grundmark B, Zethelius B, Hammar N, Walldius G, Inoue M, Holmberg L, Coolen ACC.

Stat Med. 2017 Jun 15;36(13):2100-2119. doi: 10.1002/sim.7246. Epub 2017 Feb 24.

PMID:
28233395
46.

CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer.

Tsianakas V, Harris J, Ream E, Van Hemelrijck M, Purushotham A, Mucci L, Green JS, Fewster J, Armes J.

BMJ Open. 2017 Feb 15;7(2):e013719. doi: 10.1136/bmjopen-2016-013719.

47.

Cohort Profile: The AMORIS cohort.

Walldius G, Malmström H, Jungner I, de Faire U, Lambe M, Van Hemelrijck M, Hammar N.

Int J Epidemiol. 2017 Aug 1;46(4):1103-1103i. doi: 10.1093/ije/dyw333. No abstract available.

PMID:
28158674
48.

Research engagement among black men with prostate cancer.

Toms C, Cahill F, George G, Van Hemelrijck M.

Ecancermedicalscience. 2016 Nov 24;10:695. doi: 10.3332/ecancer.2016.695. eCollection 2016.

49.

Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study.

Grootendorst MR, Cariati M, Pinder SE, Kothari A, Douek M, Kovacs T, Hamed H, Pawa A, Nimmo F, Owen J, Ramalingam V, Sethi S, Mistry S, Vyas K, Tuch DS, Britten A, Van Hemelrijck M, Cook GJ, Sibley-Allen C, Allen S, Purushotham A.

J Nucl Med. 2017 Jun;58(6):891-898. doi: 10.2967/jnumed.116.181032. Epub 2016 Dec 8.

50.

Investigating nutrition and lifestyle factors as determinants of abdominal obesity: an environment-wide study.

Wulaningsih W, Van Hemelrijck M, Tsilidis KK, Tzoulaki I, Patel C, Rohrmann S.

Int J Obes (Lond). 2017 Feb;41(2):340-347. doi: 10.1038/ijo.2016.203. Epub 2016 Nov 14.

Supplemental Content

Loading ...
Support Center